Informative Exhibition for Deprescribing Benzodiazepines

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

6410 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-13

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults. The main question it aims to answer is:

• Does an interactive and informative exhibition reduce the number of participants using benzodiazepines? Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center.

Participants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use. A single informative session on the same topic will be conducted for health professionals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anxiety Lowering and Deprescribing Through Emotion Regulation

NCT06359314

Benzodiazepine Dependence Anxiety Disorders Sleep Disturbance

COMPLETED NA

A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder

NCT00106860

Anxiety Disorder

COMPLETED PHASE3

A Study of the Effectiveness of Electronic Interventions on the Standardized Prescription Benzodiazepines and Z-drugs

NCT03724669

Bcenzodiazepines, Abuse, Retrospective Study, Focus Groups, Real-world Study

COMPLETED NA

Brief Group Psychotherapy for Anxiety and Depression

NCT04489641

Affective Disorder

COMPLETED NA

Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors

NCT00471588

Obsessive-Compulsive Disorder

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Benzodiazepine-Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Before intervention

This group will consist of patients who attended the primary care center before the implementation of the intervention.

No interventions assigned to this group

After intervention

This group will consist of patients who will attend the primary care center after the implementation of the intervention.

Informative Session

Intervention Type OTHER

The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Informative Session

The intervention consists of implementing an interactive exhibition on the risks of chronic benzodiazepine treatment in the waiting room of a primary care center. Additionally, the health professionals at the center will receive a single informative session on the same topic.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women between 18 and 99 years of age.
* Attended at the Baix-a-Mar Primary Care Center during the study period.

Exclusion Criteria

* Severe mental health disease
* Displaced patients or those who do not have an assigned doctor at the center.
* Participation in another study involving an experimental intervention during the period of the present study that affects benzodiazepine prescription.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No